Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging
US5346687A · kind A · utility
9Cited by
18References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 3, 1992 |
| Grant date | Sep 13, 1994 |
| Priority date | — |
| Expiry date | Jan 3, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibody against stage specific embryonic antigen-1 is radiolabeled by direct means with a radionuclide for use in detection of occult abscess and inflammation. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the antibody using Sn(II), or using other reducing agents followed by the addition of Sn(II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of radionuclide reducing agent, such as stannous tartrate. The resulting product may be store frozen or lyophilized, with radiolabeling accomplished by the addition of the radionuclide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.